Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Short summary

In a Phase III trial (n=144), rituximab did not significantly improve renal response rates in lupus nephritis patients treated with MMF and corticosteroids, failing to meet its primary endpoint, though it did deplete B cells and improve serological markers.

AI-generated from the title and abstract; the full text is not read.